Multiple Myeloma and EasyM Resource Centre.
Featured
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
Iain Rogers2025-03-04T10:05:19-05:00March 3rd, 2025|Publication|
Mass Spectrometry Testing in Multiple Myeloma
Iain Rogers2025-02-24T16:20:23-05:00February 11th, 2025|Articles|
M-spike and Multiple Myeloma
Iain Rogers2025-02-24T16:20:40-05:00February 5th, 2025|Articles|
Publications, Posters & Case Studies
Jenna Kerry2026-03-17T17:02:21-04:00
Sensitive Peripheral Residual Disease (PRD) Detection Using Clonotypic Mass Spectrometry in Patients with Newly Diagnosed Multiple Myeloma (NDMM): The EasyM Approach
Jenna Kerry2026-03-17T17:02:21-04:00March 17th, 2026|Poster|
Jenna Kerry2026-06-24T11:55:55-04:00
Clinical Utility of Quantitative, Mass Spectrometry-Based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-Canadian Real-World Cohort Study
Jenna Kerry2026-06-24T11:55:55-04:00February 24th, 2026|Poster|
Jenna Kerry2025-10-30T13:42:02-04:00
Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Jenna Kerry2025-10-30T13:42:02-04:00October 30th, 2025|Publication|
Articles
Press & News
Iain Rogers2025-03-21T11:58:31-04:00
ASH 2022 | Dr. Ravi Vij – VJ HemeOnc
Iain Rogers2025-03-21T11:58:31-04:00December 15th, 2022|News|